Findings suggest semaglutide and other GLP-1 agonists may significantly reduce alcohol use disorder hospitalizations, ...

The GLP-1 tirzepatide, the active ingredient in Eli Lilly's Mounjaro, was found to reduce the risk of heart failure by 46% among individuals with obesity, according to a study published Nov. 16 in The ...

A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and accompanying ...

A new study supports the notion that the same mechanisms that help folks lose weight with Ozempic and its kin also work to ...

Mohammad Ali Sheffeh, MD, from the Mayo Clinic in Rochester, Minnesota, and colleagues examined the efficacy of GLP-1 RA or SGLT-2i initiation for reducing mortality or cardiovascular events among ...

GLP-1 drug shortages, driven by cosmetic and weight loss purposes, result in access disparities among individuals with ...

Some GLP-1 receptor agonists may hold promise as treatments for alcohol use disorder (AUD), a Swedish observational study ...

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

HERSHEY, PA. — GLP-1 weight-loss drugs are having a “mild impact” on The Hershey Co.’s business, president and chief ...

For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with ...

A new warning about _____ is on all labels of GLP-1 receptor agonists. True or False: Repetitive transcranial magnetic ...

A new study provides more evidence that GLP-1 RAs don’t raise the risk for pancreatic cancer and may in fact offer some protection.